CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...